Real-World Dose Trajectory Patterns and Impact on Polypharmacy Burden and New Antiseizure Medication (ASM) Prescriptions in Patients With Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS), or Tuberous Sclerosis Complex (TSC) Receiving Cannabidiol (CBD)
Real-World Dose Trajectory Patterns and Impact on Polypharmacy Burden and New Antiseizure Medication (ASM) Prescriptions in Patients With Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS), or Tuberous Sclerosis Complex (TSC) Receiving Cannabidiol (CBD)
Challenge
Real-world dose trajectory patterns for CBD in epilepsy patients had not been characterized, limiting understanding of how CBD is optimized in clinical practice.
Solution
Target RWE researchers analyzed longitudinal CBD dose trajectory data in real-world epilepsy patients, characterizing dose titration patterns, time to stable dosing, and the relationship between dose trajectory and ASM polypharmacy burden.